Resilient device

Information

  • Patent Grant
  • 9173768
  • Patent Number
    9,173,768
  • Date Filed
    Wednesday, July 11, 2007
    16 years ago
  • Date Issued
    Tuesday, November 3, 2015
    8 years ago
Abstract
An intravaginal device has a working portion (e.g., intravaginal urinary incontinence device suppository, tampon) and an anchoring portion comprising at least one member extending beyond at least one end of the working portion to maintain the working portion in place during use.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The present invention relates to a resilient device. More specifically, this invention relates to a device that has a working portion having a variable equivalent diameter, and an anchoring mechanism. The device is useful, e.g., for reducing or preventing urinary incontinence.


2. Description of the Prior Art


Stress urinary incontinence is a problem for many women. It is characterized by leakage of urine during a stressing event, such as a cough or a sneeze. Many devices have been designed to reduce or prevent stress urinary incontinence. U.S. Pat. No. 5,603,685 teaches inflatable devices and a means to provide a device that is small for insertion into the vagina and enlarges to a required shape and pressure to reduce or prevent urinary incontinence. U.S. Pat. No. 6,090,098 teaches tampon-like devices, each made with a combination of absorbing and/or non-absorbing fibrous materials. U.S. Pat. No. 6,645,137 teaches a coil that expands in the vagina. U.S. Pat. No. 5,036,867 teaches a compressible resilient pessary. U.S. Pat. No. 6,460,542 teaches a highly shaped rigid pessary. Many patents are drawn to stents that are sized and designed to keep arteries open.


Despite the teaching of the prior art, there is a continuing need for a device suitable for insertion into a vagina and useful for reducing or preventing urinary incontinence. In addition, a need exists to provide for safe and secure anchoring of disposable intravaginal devices.


SUMMARY OF THE INVENTION

We have addressed the needs discussed above with the present invention. In one embodiment, an intravaginal device includes a working portion and an anchoring portion. The anchoring portion has at least one member extending beyond at least one end of the working portion to maintain the working portion in place during use.


In another embodiment, an intravaginal urinary incontinence device includes a stent having a working portion having opposed faces to provide support to an associated urinary system; and an anchoring portion to maintain the stent in place during use. The anchoring portion has at least one member extending beyond at least one end of the working portion.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a perspective view of a device according to the present invention;



FIG. 2 is a perspective view of the device of FIG. 1 in the insertion state while contained in an applicator.



FIG. 3 is a perspective view of the device of FIG. 1 in the use state.



FIG. 4 is a perspective view of a second device according to the present invention;



FIG. 5 illustrates several plan views of an anchoring portion according to the present invention;



FIG. 6A is a perspective view of a third device according to the present invention;



FIG. 6B is a side elevation of the device of FIG. 6A;



FIG. 7 is a side view of the device of FIG. 1;



FIG. 8 shows a bare wire form formed into an elastic structure and a coated wire form;



FIG. 9A-9C shows three alternative embodiments of a composite intravaginal device;



FIG. 10 is a device in a bag that is useful for the present invention;



FIG. 11 illustrates a tool utilized to form the devices utilized in the present invention;



FIG. 12 illustrates a tool utilized to heat-treat the devices utilized in the present invention;



FIG. 13 shows a diameter vs. pressure curve for a straight stent and a basket stent as described herein;



FIG. 14 shows a graph of the diameter versus pressure of a rabbit and flower stent;



FIG. 15 shows a graph of the diameter versus pressure of three different pressure levels of the flower stent; and



FIG. 16 shows a graph comparing the diameter versus pressure curve of two different pressure levels of the flower stent against a hybrid foam-wire device.





DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

As used herein the specification and the claims, the term “wire form” and variants thereof relate to a structure formed of at least one wire or wire-like material that is manipulated and optionally secured (e.g., by welding) in a desired three-dimensional structure.


As used herein the specification and the claims, the term “shape memory material” and variants thereof relate to materials that can be shaped into an initial shape, which initial shape can be subsequently formed into a stable second shape. The material is capable of substantially reverting to its initial shape upon exposure to an appropriate event, including without limitation mechanical deformation and a change in temperature.


As used herein the specification and the claims, the term “stent” and variants thereof relate to a device used to support a bodily orifice, cavity, vessel, and the like. The stent is resilient, flexible, and collapsible with memory. The stent may be any suitable form, including, but not limited to, scaffolding, a slotted tube or a wire form.


As used herein, a “stent” is a device used to support a bodily orifice, cavity, vessel, and the like. The stent is resilient, flexible, and collapsible with memory. The stent may be any suitable form, including, but not limited to, scaffolding, a slotted tube or a wire form.


Referring to FIGS. 1-8, there is shown a device 10 according to the present invention. The device 10 has a working portion 1 which is generally cylindrical in shape, which has a longitudinal axis, and which has opposed or outer faces 9a and 9b to provide support to an associated urinary system. Working portion 1 has an initial equivalent diameter d ranging from about 20 mm to about 170 mm and a length L1 ranging from about 15 mm to about 60 mm. Where the working portion is non-cylindrical (as shown in FIGS. 4 and 7), the equivalent diameter is the maximum distance in millimeters between the opposed or outer faces, 9a and 9b. The opposed or outer faces 9a and 9b are generally parallel to each other and to the longitudinal axis and are defined by longitudinally extending struts. As seen in FIG. 2, working portion 1 has an insertion (in an applicator or other device for insertion) equivalent diameter d 2 ranging from about 5 mm to about 20 mm. As seen in FIG. 3, working portion 1 has a use equivalent diameter (in the vagina) d 3 ranging from about 5 mm to about 40 mm. Working portion 1 may be made of any elastic material that compresses and recovers with sufficient force to provide the desired effect. In one embodiment, the working portion 1 is made of Nitinol wire 20 and comprises alternating sinusoidal struts 2, 3 which intersect and form a strut angle θ. Alternating struts 2, 3 have a length L2 and L3 equal to the working portion length. The working pressure exerted by working portion 1 is determined by the thickness of the wire, the number of wires, the length of the struts and the strut angle, and the number of times the working portion is heat-treated. The number of wires may range from about 1 to about 20. The wires may be separate, twisted, or braided. For some applications, the working portion exerts a pressure of from about 5 to about 250 cm H2O in the working state. Device 10 may also have an anchoring means, e.g., anchoring portion 4. Anchoring portion 4 is designed to keep the device in place when in use. Anchoring portion 4 is shaped suitable to keep the device in place while in use. Suitable shapes include, but are not limited to, a basket handle 5, rabbit ears 6, and a dog bone 7, as shown in FIG. 5. The anchoring portion may be made of the same material as the working portion or they may be made of different materials. The working portion and anchoring portion may be made as a uni-body construction, or may be made separately and joined by attachment means, such as silicone tubing 22. The devices may be treated to provide improved biocompatibility. The device may be placed inside tubing, for example silicone tubing, or may be dip coated in suitable polymeric materials.


Devices according to the present invention may be useful for treating or preventing urinary incontinence. For this application, the device is sized to fit comfortably in the vagina. All of the devices described below may have working portions with initial equivalent diameters of from about 20 to about 170 mm. Preferably, the working portion has a generally cylindrical working portion that may have an initial equivalent diameter ranging from about 20 to about 170 mm, preferably about 20 to about 45 mm, or more preferably about 30 mm; an insertion equivalent diameter ranging from about 5 to about 25 mm, preferably about 10 to about 20 mm, or more preferably about 18 mm; a use equivalent diameter ranging from about 20 to about 40 mm, preferably about 25 to about 30 mm, or more preferably about 25 mm; and a length ranging from about 20 to about 60 mm, preferably about 20 to about 30 mm, or more preferably about 25 mm. The anchoring portion extends beyond the working portion and may have an initial equivalent diameter ranging from about 20 to about 60 mm, preferably about 40 to about 60 mm, or more preferably about 50 mm; an insertion equivalent diameter ranging from about 10 to about 25 mm, preferably about 10 to about 20 mm, or more preferably about 18 mm; a use equivalent diameter ranging from about 20 to about 60 mm, preferably about 40 to about 60 mm, or more preferably about 50 mm; and a length ranging from about 10 to about 50 mm, preferably about 20 to about 40 mm, or more preferably about 30 mm.


For a basket stent (shown in FIGS. 6A & B), the working portion of the device has a length and equivalent diameter in the insertion state, the working state, and the removal state. The insertion state length may range from about 20 to about 30 mm, for example about 25 mm. The insertion state equivalent diameter may range from about 5 to about 20 mm, for example about 18 mm. The working state length at rest and during a cough may range from about 20 to about 30 mm, for example about 25 mm. The working state equivalent diameter at rest may range from about 20 to about 30 mm, for example about 25 mm. The working state equivalent diameter during a cough may range from about 15 to about 25 mm, for example about 20 mm. The removal state length may range from about 20 to about 30 mm, for example about 25 mm. The removal state equivalent diameter may range from about 15 to about 20 mm, for example about 18 mm.


The anchoring portion of the device has a length (LA) and width (WA) in the insertion state, the working state, and the removal state. The insertion state length may range from about 25 to about 40 mm, for example about 30 mm. The insertion state width may range from about 15 to about 20 mm, for example about 18 mm. The working state length at rest and during a cough may range from about 25 to about 40 mm, for example about 30 mm. The working state width at rest and during a cough may range from about 25 to about 35 mm, for example about 30 mm. The removal state length may range from about 30 to about 50 mm, for example about 40 mm. The removal state width may range from about 15 to about 20 mm, for example about 18 mm.


For a straight stent, the working portion of the device has a length and equivalent diameter in the insertion state, the working state, and the removal state. The insertion state length may range from about 25 to about 60 mm, for example about 45 mm. The insertion state equivalent diameter may range from about 5 to about 20 mm, for example about 18 mm. The working state length at rest and during a cough may range from about 25 to about 60 mm, for example about 45 mm. The working state equivalent diameter at rest may range from about 20 to about 30 mm, for example about 25 mm. The working state equivalent diameter during a cough may range from about 15 to about 25 mm, for example about 20 mm. The removal state length may range from about 25 to about 60 mm, for example about 45 mm. The removal state equivalent diameter may range from about 15 to about 20 mm, for example about 18 mm.


For a rabbit stent (shown in FIGS. 1 & 3), the working portion of the device has a length and equivalent diameter in the insertion state, the working state, and the removal state. The insertion state length may range from about 20 to about 30 mm, for example about 25 mm. The insertion state equivalent diameter may range from about 10 to about 20 mm, for example about 15 mm. The working state length at rest and during a cough may range from about 20 to about 30 mm, for example about 25 mm. The working state equivalent diameter at rest and during a cough may range from about 10 to about 30 mm, for example about 18 mm. The removal state length may range from about 20 to about 30 mm, for example about 25 mm. The removal state equivalent diameter may range from about 10 to about 20 mm, for example about 15 mm. The height of the working portion in all states may range from about 20 to about 30 mm, for example about 25 mm.


The anchoring portion of the device has a length and width in the insertion state, the working state, and the removal state. The insertion state length may range from about 20 to about 50 mm, for example about 30 mm. The insertion width may range from about 10 to about 20 mm, for example about 18 mm. The working state length at rest and during a cough may range from about 20 to about 50 mm, for example about 30 mm. The working state width at rest and during a cough may range from about 20 to about 60 mm, for example about 50 mm at the top and from about 10 to about 50 mm, for example about 25 mm at the bottom. The removal state length may range from about 20 to about 50 mm, for example about 30 mm. The removal state width may range from about 10 to about 20 mm, for example about 18 mm.


For a flower stent (shown in FIGS. 4 & 7), the working portion of the device has a length and equivalent diameter in the insertion state, the working state, and the removal state. The insertion state length may range from about 20 to about 30 mm, for example about 25 mm. The insertion state equivalent diameter may range from about 10 to about 20 mm, for example about 15 mm. The working state length at rest and during a cough may range from about 20 to about 30 mm, for example about 25 mm. The working state equivalent diameter at rest may range from about 20 to about 35 mm, for example about 25 mm. The working state equivalent diameter during a cough may range from about 15 to about 30 mm, for example about 20 mm. The removal state length may range from about 20 to about 30 mm, for example about 25 mm. The removal state equivalent diameter may range from about 10 to about 20 mm, for example about 15 mm.


The anchoring portion of the device has a length and width in the insertion state, the working state, and the removal state. The insertion state length may range from about 20 to about 50 mm, for example about 30 mm. The insertion width may range from about 10 to about 20 mm, for example about 18 mm. The working state length at rest and during a cough may range from about 20 to about 60 mm, for example about 30 mm. The working state width at rest and during a cough may range from about 20 to about 60 mm, for example about 30 mm at the top and from about 10 to about 50 mm, for example about 20 mm at the bottom. The removal state length may range from about 20 to about 60 mm, for example about 30 mm. The removal state width may range from about 10 to about 20 mm, for example about 18 mm.


In one embodiment of the present invention, the working portion of the intravaginal devices is a stent. In other embodiments, the working portion may be a suppository, a vaginal tampon, a bladder support, and a combination thereof. Elements of the devices of the present invention may be made from any elastic or supereleastic material. Suitable materials include, but are not limited to metals including metal alloys, for example a nickel-titanium (“NiTi”) alloy known in the art as Nitinol. As is known in the art, there are a variety of ways to process NiTi, including resistance heating and permanent deformation to create a shape set. Other materials (other alloys, superelastic alloys or other NiTi compositions) may be utilized to make devices according to the present invention. Additionally, polymers including shape memory polymers (SMPs) may also be used in addition to or in place of the metals.


Shape memory is the ability of a material to remember its original shape, either after mechanical deformation, which is a one-way effect, or by cooling and heating which is a two-way effect. This phenomenon is based on a structural phase transformation. The first materials to have these properties were shape memory metal alloys including NiTi (Nitinol), CuZnAl (the first copper based SMA to be commercially exploited and the alloys typically contain 15-30 wt % Zn and 3-7 wt % Al), CuAlNi (may now be preferred to the CuZnAl; Cu13Al4Ni is one that is often used commercially), CuAlBe (a Cu12Al doped with less than 0.5% of beryllium), and FeNiAl alloys. Strains of up to about 10% can be fully recovered in these alloys. Examples of suitable alloys further include Algiloy, Stainless Steel, for example 304 stainless steel, and carbon spring steels. The structure phase transformation of these materials is known as martensitic transformation.


SMPs are light, high in shape memory recovery ability, easy to manipulate and process, and economical compared to shape memory alloys. These materials are also useful for devices according to the present invention. There are few ways to achieve the shape memory properties. SMPs are characterized as phase segregated linear block co-polymers (e.g., thermoplastic elastomers) having a hard segment and soft segment that form physical cross-links. The hard segment is typically crystalline with a defined melting point, and the soft segment is typically amorphous with a defined glass transition temperature. The transition temperature of the soft segment is substantially less than the transition temperature of the hard segment. Examples of these materials include polyurethanes; polyether amides; polyether ester; polyester urethanes; polyether urethanes; and polyurethane/urea. SMPs are also formed by covalently cross-linked irreversible formation of the permanent shape. Different parameters that can be tailored for these materials are mechanical properties of permanent and temporary shape, customized thermal transitions, and kinetics of shape memory effect. SMPs can be biostable and bioabsorbable. Biostable SMPs are generally polyurethanes, polyethers, polyacrylates, polyamides, polysiloxanes, and their copolymers. Bioabsorbable SMPs are relatively new and include thermoplastic and thermoset materials. Shape memory thermosets may include poly (caprolactone) dimethyacrylates; and shape memory thermoplastics may include combinations of different monomers to prepare polyester based copolymers.


When the SMP is heated above the melting point of the hard segment, the material can be shaped. This “original” shape can be memorized by cooling the SMP below the melting point of the hard segment. When the shaped SMP is cooled below the glass transition temperature of the soft segment while the shape is deformed, a new “temporary” shape is fixed. The original shape is recovered by heating the material above the glass transition temperature of the soft segment but below the melting point of the hard segment. The recovery of the original shape induced by an increase of temperature is called the thermal shape memory effect. Several physical properties of SMPs other than ability to memorize shape are significantly altered in response to external changes in temperature and stress, particularly at the glass transition of the soft segment. These properties include elastic modulus, hardness, and flexibility. The modulus of SMP can change by a factor of up to 200 when heated above the glass transition temperature of the soft segment. In order to prepare devices that will have sufficient stiffness, it is necessary to have thermal transitions such that the material will have high modulus at use temperature. For example, if a device is going to be used at body temperature, then the transition temperature may be higher than 37° C. (example 45-50° C.) so that upon cooling to 37° C. the modulus is high and thereby providing sufficient stiffness. It is also important to design the device such that it will compensate for lower physical properties compared to shape memory metal alloys. Some of the design features may include higher wall thickness; short connectors; or hinge points at appropriate locations. These materials can overcome some of the limitations with viscoelastic polymer properties such as creep and stress relaxation.


SMP can also be prepared by using TPEs prepared from hydrophilic polymers so that the phase transition can be also occur by physical changes due to moisture absorption. Examples of these TPEs are hydrophilic polymer ester amide (Pebax) and hydrophilic polyurethanes prepared by Eld Atochem and CardioTec International, respectively. Devices prepared from these materials will be soft and will be easier to remove after its use.


The shape memory materials may be formed of or at least enclosed within biocompatible materials, preferably materials that are approved for use in the human body. For example, medical grade silicone rubber may enclose a wire form device. This may be achieved through one or more tubular sheaths about the wire or as a coating prepared on the wire.


As indicated above, the device may be made as a uni-body construction, or it may be a composite device, e.g., the working portion and anchoring portion may be made separately and joined by attachment means, such as silicone tubing. Additional elements features may be included to provide desired characteristics. In addition to improved biocompatibility, polymeric materials may cushion the device to minimize the risk of tissue damage.


For example, each working surface may have a pad 30 to distribute the forces directed toward the vaginal walls, thereby reducing the unit pressure applied by the device. This soft, resilient cushion could be made out of various types of medical grade sponges and foams (such as those formed from HYPOL™ Hydrophilic Polyurethane Prepolymers from Dow Chemical Company), thermoplastic elastomers (“TPE”), silicones, fibers, and the like.


As shown in FIG. 8, the device includes a wire form 50 formed into an elastic structure having an anchoring portion 52 and a working portion 54. The wire form 50 has a biocompatible polymer coating 56 disposed thereon. In the device of FIG. 8, the coating 56 has enlarged regions, each forming a pad 58 on one of the working surfaces of the working portion 54.


In the alternative embodiments shown in FIG. 9A, the device may replace the full coating of FIG. 8 with tubing 56′ and a single compressible foam working portion 54′. The embodiment of FIG. 9B, employs two separate pad elements 58″ as the working portion 54″. The wire form 50″ that extends to form the anchoring portion 52″ provides elasticity to the pad elements 58″ to support the urinary system. The embodiment of FIG. 9C incorporates the Rabbit stent anchoring portion 52′″ and replaces the working portion wire form with an enlarged pad structure 54′″. Again, this enlarged pad structure may be formed of any appropriate resilient material including foams, fibrous structures, and the like.


In addition, the pessary 10 may be loaded with various pharmacological compounds and additives, such as hormones and/or alpha-adrenoceptor agonists, urethra selective stimulators, prostaglandins, anticholinergics, hormones, nicotine, cytostatics, tranquilizers, local anaesthetics and other compounds, such as pharmacologically active alpha-[tertiary-aminomethyl]-benzenemethanol derivatives and other compounds as disclosed in U.S. Pat. No. 5,527,821 to Willman et al., as well as toxin inhibitors such as glyceryl monolaurate and related compounds as disclosed in Brown-Skrobot et al., U.S. Pat. No. 5,547,985, each of which is incorporated by reference herein.


Methods of associating drugs, hormones or other pharmacological compounds with an object for drug administration to the body are well known to those skilled in the art, as for example, described in U.S. Pat. No. 5,188,835 and German Patent No. 198 29 713, both incorporated in their entirety by reference herein. In still a further embodiment, topical medications, ointments or creams can be associated with pessary 10 by infusion (injection), coating or absorption into the pores of a sponge-like material of the medication of the pessary 10 and slowly released, within a day or two, into the vaginal cavity. This embodiment of the invention may be used for treating dryness, irritation, or other local conditions. The ointment, cream, etc., can be replenished into the pessary on an as needed basis.


As shown in FIG. 10, the intravaginal devices also may be enclosed in a sheet-like material 60 that may reduce friction during deployment, shield a wire form from view (to be aesthetically pleasing), help control the device during insertion and removal, help the device to stay in place, contain absorbent fibers of a tampon, contain a suppository substance, and/or create more contact area for applying pressure to the bladder neck. The sheet-like material may be formed into a cover or flexible bag 62 that may also provide increased friction against the vaginal epithelium in comparison to a silicone-coated wire form to reduce the likelihood of undesired movement during use, e.g., becoming skewed. Any medically appropriate sheet-like materials may be used to form the cover or bag, and depending upon the desired end-use, it may be opaque, light, and/or breathable. Useful sheet-like materials include those used in the manufacture of tampons, such as nonwoven fabrics and plastic film, including apertured films. The cover or bag itself may also be apertured.


The device preferably includes a withdrawal element such as a removal string 64. This may be crisscrossed between the struts of the device to create a “cinch sac” mechanism. Any string or cord known in the sanitary protection art may be useful for this purpose. As the strings are pulled during removal, the struts are gathered together to create a smaller diameter device during removal. Cinching the device at its base may make removal of the device more comfortable and easier as it makes the diameter of the device smaller and the shape conducive to remove easily.


The device may be contained within an applicator 66 similar to those known for use in delivering tampons and suppositories as shown in FIG. 2. The applicator may be a push-type applicator or a retractable applicator. A collar 68 may be added to control the depth of insertion.


EXAMPLES

The following examples are illustrative of devices according to the present invention. The claims should not be construed to be limited to the details thereof.


Prototype devices were modeled in shape and scale after existing, predicate vaginal pessary devices. There were two geometries presented for this device. The expanded stent device was approximately 35 mm in diameter and 55 mm long. The first of the proposed geometries was a simple S-shaped stent like a ring; the second resembled the form of a handled basket and was modeled in the form of the classic “ring” pessary. In its design the “basket” portion was approximately 25 mm high and the “handle” made up the balance of the overall length.


Both are assemblies of four known medical materials. The collapsed vaginal stents were enclosed in a commercial plastic tampon applicator. The working assemblies were made up of a nickel-titanium wire form (Nitinol), which was covered by a medical grade silicone rubber (silastic) tube. This covered wire form “stent” was placed in a heat-sealed bag made of the same standard non-woven polypropylene material used in tampon covers. This covered device was made to be easily removable by the addition of a tampon cotton string, as a cinch and removal pull.


The nickel-titanium wire used in these prototypes was the same alloy as used in vascular systems. Post-shape-setting processing of the metal does not effect corrosion and biocompatibility of the device. The silicone tubing was also a known medical grade material. The silastic tubing was Dow Q7-4750.


The general procedure was to shape an SE508 NiTi into the design on a form using one or multiple steps heating the fixture and form to about 500° C. for at least one minute for each step. Any excess wire was cut from the form. As is known in the art, the wire may be chemically etched to provide further biocompatibility. The wire was enclosed in a rubbery polymer coating such as silicone assuring to fasten the wire ends such that they may not puncture the surface.


Example 1
Rabbit Flat Pessary

Approximately 1 foot of straightened and etched SE508 wire, 0.0315″ diameter was obtained. The tool 100 pictured in FIG. 11 was made using conventional techniques known in stent art. In a smooth upswing, the wire was wrapped around the pins in the following order to create the pattern: P7, P3, P1CC, P3, P6CC, P3, P6, P4, P8CC, P5, P8, P5, P2CC, P5, P7, P1CC, P3, P7 (the wrapping was clockwise, unless indicated by “CC”). The zigzag wrapping pattern was smoothly discontinued and the final end of the wire was poked through holes in the fixture to secure it. A large hose clamp was wrapped around the fixture, over the zigzag portion. The clamp was tightened to keep the wires in position, but not so much as to compress the wires to the surface of the fixture. The wound wire was heat treated on the fixture for 3 minutes in a 505C (calibrated) salt pot, then quenched with water. The heat-treated wire was removed from the fixture by unwinding it. The wire was trimmed at point P3 allowing for overlap along the “ear” and the overlapping wires were wrapped to hold them together with NiCr wire. A secondary heat treatment fixture 102 shown in FIG. 12 was made according to methods known in the art. The wire was aligned to form onto the fixture. The ends of the wire were ground to remove sharp and jagged edges.


The wire form component was passivated by methods known in the art to optimize biocompatibility. Some wire form components were etched or chemically processed to optimize biocompatibility. The parts were moved to a clean room and dipped in denatured alcohol before being placed on a clean table. All tools were cleaned with isopropyl alcohol as well as gloved hands before touching parts from denatured alcohol solution. Tubing was cleaned with Isopropyl alcohol by dripping through with a disposable pipette. The tube was dried by wicking onto a paper towel. The tube was filled with 2-4 inches of lubricant mineral oil from a syringe. Pressed fingers were run along the tube to spread the oil evenly along the inside. The tubing was slid over the wire carefully paying attention that the wire ends did not poke through the tubing. The tubing was pulled back to expose both wire ends. The ends were lined up so that the ear rests naturally. Forceps were used to hold the tubing back from the wire ends. Shrink tube was placed across the wire ends and heated to hold wire ends in place. The tubing was slid over the shrink tube section. Tubing ends were overlapped by at least 0.5 cm by pressing the ends together.


Example 2
Flower Flat Pessary

Approximately 1 foot of straightened and etched SE508 wire, 0.0315″ diameter was obtained. The tool 100 pictured in FIG. 11 was made using conventional techniques known in stent art. In a smooth upswing, the wire was wrapped around the pins in the following order to create the pattern: P6, P3, P1CC, P3, P6, P4, P7, P6, P3, P1CC, P3, P6, P4, P7, P5, P2CC, P5, P7, P4, P6, P3, P1CC, P3, P5, P2CC, P5, P7, P4, P6, P3, P1CC, and P3. The zigzag-wrapping pattern was smoothly discontinued and the final end of the wire was poked through holes in the fixture to secure it. A large hose clamp was wrapped around the fixture, over the zigzag portion. The clamp was tightened to keep the wires in position, but not so much as to compress the wires to the surface of the fixture. The wound wire was heat treated on the fixture for 3 minutes in a 505C (calibrated) salt pot, then quenched with water. The heat-treated wire was removed from the fixture by unwinding it. The wire was trimmed at point P3 allowing for overlap along the “ear” and the overlapping wires were wrapped to hold them together with NiCr wire. A secondary heat treatment fixture 102 shown in FIG. 12 was made according to methods known in the art. The wire was aligned to form onto the fixture. The ends of the wire were ground to remove sharp and jagged edges. The wire form component was passivated by methods known in the art to optimize biocompatibility. Some wire form components were etched or chemically processed to optimize biocompatibility. The parts were moved to a clean room and dipped in denatured alcohol before being placed on a clean table. All tools were cleaned with isopropyl alcohol as well as gloved hands before touching parts from denatured alcohol solution. Tubing was cleaned with Isopropyl alcohol by dripping through with a disposable pipette. The tube was dried by wicking onto a paper towel. The tube was filled with 2-4 inches of lubricant mineral oil from a syringe. Pressed fingers were run along the tube to spread the oil evenly along the inside. The tubing was slid over the wire carefully paying attention that the wire ends did not poke through the tubing. The tubing was pulled back to expose both wire ends. The ends were lined up so that the ear rests naturally. Forceps were used to hold the tubing back from the wire ends. Shrink tube was placed across the wire ends and heated to hold wire ends in place. The tubing was slid over the shrink tube section. Tubing ends were overlapped by at least 0.5 cm by pressing the ends together.


Example 3
Multi-Wire Flower Pessary

The level of severity of incontinence varies greatly from woman to woman and changes throughout a woman's life. Mechanically, this level is determined by the support of the pelvic floor musculature. When this muscle system is weakened, the urethra does not properly close when intra-abdominal pressure is exerted onto the bladder. In order to address the various levels of support of the pelvic floor musculature, there are three pressure levels of the device: Pressure 1 (for women who need minimal amount of support), Pressure 2 (for moderate support), and Pressure 3 (for women who need the greatest support).


To test this concept, the device of Example 2 was reproduced in these three different pressure levels: Pressure 1 was formed with two wires generally as described above in Example 2; Pressure 2 was formed with three wires; and Pressure 4 was formed with four wires.


Example 4
Composite Flower Pessary

The device of Example 2 was reproduced with the wire form working portion with a pair of separate foam pad elements. The wire form that extends to form the anchoring portion provides elasticity to the pad elements to support the urinary system.


Examples 1-4

Each of the exemplary devices were tested to determine the outward pressure exerted as it expands from a compressed state as described below, and the resulting diameter vs. pressure curves are shown in FIGS. 13-16.


Expansion Pressure Test


The expansion pressure test was used to determine the outward pressure the device was able to exert as it expanded from its compressed insertion state to its deployed or use state in the body. Equilibrium of the expansion pressure and the internal resistance of the body determined the diameter of the device in place.


The outward pressure the device exerts at various compression states (insertion, during use at rest, and during use under stress) was measured using a simple linear scale (Mettler PK 4800 scale). The pressure the device exerted as well as the diameter of the device were measured and recorded.


The device is tested by placing the device between the scale and a custom-made arm that compresses the device at known, incremental distances, measured in mm. The device was measured first at its free state (i.e., for rabbit: 20 mm) and then slowly compressed in increments (i.e. 1 mm or 5 mm). The force that the device exerts on the scale at known compression increments was measured in grams. The pressure was calculated by converting the force measurement from grams to pounds-force. The pounds-force was then converted to PSI units by dividing the pound-force by the contact area of the device. The contact area of the device was defined as the working portion of the device. The PSI units were then converted into cm H2O pressure. The resulting device diameter (mm) versus pressure (cm H2O) was then graphed.


This Pressure Curve Slope illustrates outward pressure that the device exerts on the body varies with device compression. This pressure increases as compression increases and reduces as the device is unloaded. This is an important behavior of our device because at rest, the pressure in the vagina is low (approximately 35 cm H2O). When a woman has a stress event such as coughing or sneezing, high intra-abdominal pressure as much as over 140 cm H2O is exerted on the bladder in a very short time period. When this event occurs, the device needs to quickly react to this sudden increase in pressure.


When the device is at rest, the device is compressed to about 20-25 mm. When a sudden intra-abdominal pressure is exerted on the device, the device is compressed down to 10-15 mm. At rest, it is important to that the pressure that the device exerts on the body is low for comfort and safety. When the device is compressed during high intra-abdominal pressure events, the device needs to exert adequate pressure quickly and then relax to its original low resting pressure when the stress event is completed.


The devices similar to those of Example 3 may be used to illustrate the desired dynamic elasticity of the intravaginal urinary incontinence device. The following table illustrates desired Expansion Pressure targets when the Low-, Medium-, and High-support devices are compressed to the specified diameter—e.g., a Resting Diameter of 25 mm or a Compressed Diameter of 10 mm.

















Pressure at 25 mm
Pressure at 10 mm



# of
Resting Diameter
Compressed Diameter


Device
Wires
(cm H2O)
(cm H2O)







Low
2
25
100


Moderate
3
50
175


High
4
75
225









More generally, the elastic working portion preferably has a first use equivalent diameter (a “Resting Diameter”) of at least about 15 mm under an expansion pressure of 20 cm H2O. This reflects the device under normal use conditions. A more preferred first use equivalent diameter is at least about 20 mm under an expansion pressure of 35 cm H2O.


A second use equivalent diameter of about 5 to about 25 mm under an expansion pressure of 100 cm H2O reflects the device under stress use conditions, such as a sneeze. A more preferred second use equivalent diameter is at least about 10 mm under an expansion pressure of 140 cm H2O.


Preferably, the second use equivalent diameter is less than the first use equivalent diameter. More preferably, the second use equivalent diameter is less than the first use equivalent diameter and at least about 20% of the first use equivalent diameter.


A third use equivalent diameter of about 10 to about 20 under expansion pressure of 150 cm H2O reflects severe stress use conditions.

Claims
  • 1. An intravaginal urinary incontinence device having a longitudinal axis and comprising a substantially hollow elastic working portion comprising a plurality of at least three longitudinally extending struts, each of which is substantially parallel to the longitudinal axis, and at least partially define outer surfaces of the device having a first use equivalent diameter of at least about 15 mm under an expansion pressure of 20 cm H2O, and a second use equivalent diameter less than the first use equivalent diameter at the same expansion pressure, wherein the diameters are measured as a maximum distance between the outer surfaces of the device.
  • 2. The incontinence device of claim 1, wherein the working portion has a third use equivalent diameter of about 10 to about 20 under expansion pressure of 150 cm H2O.
  • 3. The incontinence device of claim 1, wherein the first use equivalent diameter is at least about 20 mm under an expansion pressure of 35 cm H2O and the second use equivalent diameter is at least about 10 mm under an expansion pressure of 140 cm H2O.
  • 4. The incontinence device of claim 1, wherein the working portion comprises a structure selected from the group consisting of a slotted tube, a wire form, and combinations thereof.
  • 5. The incontinence device of claim 1, wherein the elastic working portion comprises a material selected from the group consisting of polymers, metals, and combinations thereof.
  • 6. The incontinence device of claim 1, further comprising an anchoring portion comprising at least one member extending longitudinally beyond at least one end of the working portion to maintain the working portion in place during use.
  • 7. The incontinence device of claim 6, wherein the at least one member of the anchoring portion is a looped member extending longitudinally beyond at least one end of the working portion and returning to the working portion.
  • 8. The incontinence device of claim 6, wherein the anchoring portion is arranged and configured to engage walls of a user's vaginal fornices.
  • 9. The incontinence device of claim 6, wherein the anchoring portion comprises at least two members extending longitudinally beyond the at least one end of the working portion.
  • 10. The incontinence device of claim 6, wherein the anchoring portion comprises a shape selected from the group consisting of a basket handle, a dog bone, a rabbit ear, and combinations thereof.
  • 11. The incontinence device of claim 8, comprising a cushioning material on the anchoring portion arranged and configured to engage walls of a user's vaginal fornices.
  • 12. An intravaginal urinary incontinence device comprising: a) an elastic working portion comprisingi) opposed working surfaces to provide support to an associated urinary system; andii) a cushion comprising a soft, resilient material that is associated with each of the working surfaces; andb) an anchoring portion operatively connected to the working portion to maintain the working portion at a desired location within a user's vagina;
  • 13. The incontinence device of claim 12, wherein the working portion comprises a structure selected from the group consisting of a slotted tube, a wire form, and combinations thereof.
  • 14. The incontinence device of claim 12, wherein the cushion comprises a material selected from the group consisting of sponges and foams, thermoplastic elastomers, silicones, fibers, and combinations thereof.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. application Ser. No. 11/456,376 filed Jul. 10, 2006, and is a continuation-in-part of U.S. application Ser. No. 11/456,390 filed Jul. 10, 2006, and is a continuation-in-part of U.S. application Ser. No. 11/456,402 filed Jul. 10, 2006, the complete disclosures of which are hereby incorporated herein by reference for all purposes.

US Referenced Citations (258)
Number Name Date Kind
1926518 Findley Sep 1933 A
3706311 Kokx et al. Dec 1972 A
3726277 Hirschman Apr 1973 A
4019498 Hawtrey et al. Apr 1977 A
4048998 Nigro Sep 1977 A
4139006 Corey Feb 1979 A
4290420 Manetta Sep 1981 A
4320751 Loeb Mar 1982 A
4347209 Suzuki Aug 1982 A
4669478 Robertson Jun 1987 A
4677967 Zartman Jul 1987 A
4733665 Palmaz Mar 1988 A
4739762 Palmaz Apr 1988 A
4776337 Palmaz Oct 1988 A
4856516 Hillstead Aug 1989 A
4875898 Eakin Oct 1989 A
4920986 Biswas May 1990 A
4986823 Anderson Jan 1991 A
5007894 Enhorning Apr 1991 A
5036867 Biswas Aug 1991 A
5041077 Kulick Aug 1991 A
5045079 West Sep 1991 A
5102417 Palmaz Apr 1992 A
5116365 Hillstead May 1992 A
5224494 Enhorning Jul 1993 A
5234456 Silvestrini Aug 1993 A
5306294 Winston Apr 1994 A
5366504 Andersen Nov 1994 A
5387206 Valentine Feb 1995 A
5425765 Tiefenbrun Jun 1995 A
5494029 Lane Feb 1996 A
5501063 Tews et al. Mar 1996 A
5514176 Bosley, Jr. May 1996 A
5540713 Schnepp-Pesch Jul 1996 A
5545209 Roberts Aug 1996 A
5591199 Porter Jan 1997 A
5593442 Klein Jan 1997 A
5601593 Freitag Feb 1997 A
5603685 Tutrone, Jr. Feb 1997 A
5603698 Roberts Feb 1997 A
5607445 Summers Mar 1997 A
5611768 Tutrone, Jr. Mar 1997 A
5618256 Reimer Apr 1997 A
5618301 Hauenstein Apr 1997 A
5628787 Mayer May 1997 A
5628788 Pinchuk May 1997 A
5643312 Fischell Jul 1997 A
5645559 Hachtman Jul 1997 A
5674241 Bley Oct 1997 A
5690670 Davidson Nov 1997 A
5695517 Marin Dec 1997 A
5697971 Fischell Dec 1997 A
5716396 Williams, Jr. Feb 1998 A
5723003 Winston Mar 1998 A
5749918 Hogendijk May 1998 A
5776161 Globerman Jul 1998 A
5779729 Severini Jul 1998 A
5785640 Kresch Jul 1998 A
5788979 Alt Aug 1998 A
5795346 Achter et al. Aug 1998 A
5800338 Kollerup Sep 1998 A
5800519 Sandock Sep 1998 A
5800520 Fogarty Sep 1998 A
5813973 Gloth Sep 1998 A
5814063 Freitag Sep 1998 A
5817100 Igaki Oct 1998 A
5820918 Ronan Oct 1998 A
5827321 Roubin Oct 1998 A
5833707 McIntyre Nov 1998 A
5840081 Andersen Nov 1998 A
5843161 Solovay Dec 1998 A
5843176 Weier Dec 1998 A
5855600 Alt Jan 1999 A
5873906 Lau Feb 1999 A
5879370 Fischell Mar 1999 A
5879381 Moriuchi Mar 1999 A
5888201 Stinson Mar 1999 A
5891191 Stinson Apr 1999 A
5895406 Gray Apr 1999 A
5902332 Schatz May 1999 A
5911732 Hojeibane Jun 1999 A
5911752 Dustrude Jun 1999 A
5913897 Corso, Jr. Jun 1999 A
5922019 Hankh Jul 1999 A
5922020 Klein Jul 1999 A
5925353 Mosseri Jul 1999 A
5938682 Hojeibane Aug 1999 A
5948191 Solovay Sep 1999 A
5957949 Leonhardt Sep 1999 A
5976152 Regan Nov 1999 A
5980553 Gray Nov 1999 A
5988169 Anderson Nov 1999 A
5997467 Connolly Dec 1999 A
6013036 Caillouette Jan 2000 A
6019779 Thorud Feb 2000 A
6030375 Anderson Feb 2000 A
6035238 Ingle et al. Mar 2000 A
6048306 Spielberg Apr 2000 A
6053940 Wijay Apr 2000 A
6063113 Kavteladze et al. May 2000 A
6086604 Fischell Jul 2000 A
6090038 Zunker Jul 2000 A
6090098 Zunker Jul 2000 A
6106530 Harada Aug 2000 A
6110099 Benderev Aug 2000 A
6129755 Mathis Oct 2000 A
6142928 Zunker Nov 2000 A
6158435 Dorsey Dec 2000 A
6162243 Gray Dec 2000 A
6176872 Miksza Jan 2001 B1
6183456 Brown Feb 2001 B1
6183681 Sullivan et at Feb 2001 B1
6189535 Enhorning Feb 2001 B1
6190403 Fischell Feb 2001 B1
6190406 Duerig Feb 2001 B1
6197051 Zhong Mar 2001 B1
6210429 Vardi Apr 2001 B1
6241738 Dereume Jun 2001 B1
6245103 Stinson Jun 2001 B1
6251134 Alt Jun 2001 B1
6254627 Freidberg Jul 2001 B1
6254633 Pinchuk Jul 2001 B1
6261305 Marotta Jul 2001 B1
6270524 Kim Aug 2001 B1
6273895 Pinchuk Aug 2001 B1
6287315 Wijeratne Sep 2001 B1
6299573 Hull, Jr. et al. Oct 2001 B1
6312419 Durel-Crain Nov 2001 B1
6319275 Lashinski Nov 2001 B1
6325825 Kula Dec 2001 B1
6342049 Nichols Jan 2002 B1
6350248 Knudson Feb 2002 B1
6375676 Cox Apr 2002 B1
6415484 Moser Jul 2002 B1
6418930 Fowler Jul 2002 B1
6423091 Hojeibane Jul 2002 B1
6436428 Mahashabde Aug 2002 B1
6458072 Zunker Oct 2002 B1
6460542 James Oct 2002 B1
6462169 Shalaby Oct 2002 B1
6470890 Diokno Oct 2002 B1
6478726 Zunker Nov 2002 B1
6478813 Keith Nov 2002 B1
6488702 Besselink Dec 2002 B1
6503190 Ulmsten Jan 2003 B1
6530879 Adamkiewicz Mar 2003 B1
6530951 Bates Mar 2003 B1
6537293 Berryman Mar 2003 B1
6540775 Fischell Apr 2003 B1
6547817 Fischell Apr 2003 B1
6558370 Moser May 2003 B2
6562064 deBeer May 2003 B1
6562067 Mathis May 2003 B2
6572643 Gharibadeh Jun 2003 B1
6585755 Jackson et al. Jul 2003 B2
6585773 Xie Jul 2003 B1
6602281 Klein Aug 2003 B1
6605111 Bose Aug 2003 B2
6605294 Sawhney Aug 2003 B2
6612977 Staskin Sep 2003 B2
6645136 Zunker Nov 2003 B1
6645137 Ulmsten Nov 2003 B2
6652544 Houser Nov 2003 B2
6666881 Richter Dec 2003 B1
6669707 Swanstrom Dec 2003 B1
6676594 Zunker Jan 2004 B1
6676692 Rabkin Jan 2004 B2
6676694 Weiss Jan 2004 B1
6679831 Zunker Jan 2004 B1
6695763 Zunker Feb 2004 B2
6695876 Marotta Feb 2004 B1
6699274 Stinson Mar 2004 B2
6702281 Post et al. Mar 2004 B2
6702846 Mikus et al. Mar 2004 B2
6739340 Jensen May 2004 B1
6752950 Clarke Jun 2004 B2
6764503 Ishimaru Jul 2004 B1
6770025 Zunker Aug 2004 B2
6786904 Döscher Sep 2004 B2
6808485 Zunker Oct 2004 B2
6881222 White Apr 2005 B2
6997952 Furukawa et al. Feb 2006 B2
7036511 Nissenkorn May 2006 B2
7214219 Intravartolo et al. May 2007 B2
7553273 Ferguson et al. Jun 2009 B2
7717892 Bartning et al. May 2010 B2
8608639 Bartning et al. Dec 2013 B2
8613698 Bartning et al. Dec 2013 B2
9050183 Bartning et al. Jun 2015 B2
20010007081 Caprio Jul 2001 A1
20010016726 Dubrul Aug 2001 A1
20010053932 Phelps Dec 2001 A1
20020032486 Lazarovitz Mar 2002 A1
20020068975 Teitelbaum Jun 2002 A1
20020082610 Cioanta Jun 2002 A1
20020083949 James Jul 2002 A1
20020087176 Greenhalgh Jul 2002 A1
20020087186 Shelso Jul 2002 A1
20020116046 DiCaprio Aug 2002 A1
20020133183 Lentz Sep 2002 A1
20020138134 Kim Sep 2002 A1
20020156343 Zunker Oct 2002 A1
20020165521 Cioanta Nov 2002 A1
20020179093 Adamkiewicz Dec 2002 A1
20020183711 Moser Dec 2002 A1
20030015203 Makower Jan 2003 A1
20030018377 Berg Jan 2003 A1
20030040754 Mitchell Feb 2003 A1
20030040771 Hyodoh Feb 2003 A1
20030125603 Zunker Jul 2003 A1
20030187494 Loaldi Oct 2003 A1
20040049211 Tremulis Mar 2004 A1
20040077924 Zunker Apr 2004 A1
20040078013 Zunker Apr 2004 A1
20040122285 Zunker Jun 2004 A1
20040148010 Rush Jul 2004 A1
20040158122 Guerquin Aug 2004 A1
20040210211 Devens Oct 2004 A1
20040230284 Headley Nov 2004 A1
20040249238 Farrell Dec 2004 A1
20040249352 Swick Dec 2004 A1
20040249433 Freitag Dec 2004 A1
20040267280 Nishide Dec 2004 A1
20050010285 Lambrecht Jan 2005 A1
20050016545 Nissenkorn Jan 2005 A1
20050085923 Levine Apr 2005 A1
20050096673 Stack May 2005 A1
20050096721 Mangin May 2005 A1
20050096732 Marotta May 2005 A1
20050125020 Meade et al. Jun 2005 A1
20050250978 Kammerer Nov 2005 A1
20050268573 Yan Dec 2005 A1
20060100478 Connors et al. May 2006 A1
20060161187 Levine et al. Jul 2006 A1
20060178694 Greenhalgh et al. Aug 2006 A1
20070203429 Ziv Aug 2007 A1
20070244352 Ziv Oct 2007 A1
20080009662 Bartning et al. Jan 2008 A1
20080009663 Bartning et al. Jan 2008 A1
20080009664 Bartning et al. Jan 2008 A1
20080009666 Bartning et al. Jan 2008 A1
20080009814 Bartning et al. Jan 2008 A1
20080009931 Bartning et al. Jan 2008 A1
20080033230 Banning et al. Feb 2008 A1
20080033231 Bartning et al. Feb 2008 A1
20080188924 Prabhu Aug 2008 A1
20080234831 Clarke et al. Sep 2008 A1
20080281149 Sinai et al. Nov 2008 A1
20090203959 Ziv et al. Aug 2009 A1
20090266367 Ziv et al. Oct 2009 A1
20100218359 Bartning et al. Sep 2010 A1
20110077578 Bartning et al. Mar 2011 A1
20110152604 Hull, Jr. et al. Jun 2011 A1
20110152605 Hull, Jr. et al. Jun 2011 A1
20120136199 Hou et al. May 2012 A1
20130160272 Bartning et al. Jun 2013 A1
20130165742 Bartning et al. Jun 2013 A1
20130211185 Hull, Jr. et al. Aug 2013 A1
Foreign Referenced Citations (43)
Number Date Country
684733 Jul 1994 AU
101522140 Sep 2009 CN
202006004901 Jul 2006 DE
0 264 258 Apr 1988 EP
0 498 912 Aug 1992 EP
0 556 908 Aug 1993 EP
0 625 890 Nov 1994 EP
0 663 197 Jul 1995 EP
0 663 197 Jul 1995 EP
0 700 669 Mar 1996 EP
0 955 024 Nov 1999 EP
0 963 217 Dec 2004 EP
1 837 151 Sep 2007 EP
2364645 Feb 2002 GB
2007185914 Jul 2007 JP
2150919 Jun 2000 RU
2150919 Jun 2000 RU
WO 8810106 Dec 1988 WO
WO 9505790 Mar 1995 WO
WO 9610965 Apr 1996 WO
WO 9734550 Sep 1997 WO
WO 9834677 Aug 1998 WO
WO 9842281 Oct 1998 WO
WO 9922680 May 1999 WO
WO 9959477 Nov 1999 WO
WO 0003659 Jan 2000 WO
WO 0067662 Nov 2000 WO
WO 0167983 Sep 2001 WO
WO 0170154 Sep 2001 WO
WO 0226160 Apr 2002 WO
WO 0228313 Apr 2002 WO
WO 03047476 Jun 2003 WO
WO 2004026196 Apr 2004 WO
WO 2004103213 Dec 2004 WO
WO 2005087153 Sep 2005 WO
WO 2005087154 Sep 2005 WO
WO 2006097935 Sep 2006 WO
2008008794 Jan 2008 WO
WO 2008010214 Jan 2008 WO
WO 2008152628 Dec 2008 WO
WO 2009044394 Apr 2009 WO
2009079607 Jun 2009 WO
WO 2009130702 Oct 2009 WO
Non-Patent Literature Citations (101)
Entry
Bachmann, et al., “External Occlusive Devices for Management of Female Urinary Incontinence”, Journal of Women's Health, vol. 11, No. 9, 2002, publisher: Mary Ann Liebert, Inc., pp. 793-800.
In the U.S. Appl. No. 11/456,376, filed Jul. 10, 2006 the Restriction Requirement dated Nov. 20, 2008.
In the U.S. Appl. No. 11/456,376, filed Jul. 10, 2006 the Final Rejection dated Feb. 15, 2012.
In the U.S. Appl. No. 11/456,402, filed Jul. 10, 2006 the Final Rejection dated Apr. 4, 2012.
In the U.S. Appl. No. 11/456,424, filed Jul. 10, 2006 the Notice of Allowance dated Feb. 16, 2012.
In re the U.S. Appl. No. 11/456,376 (2008/0009662A1) the non-final rejection dated Mar. 10, 2009.
In re the U.S. Appl. No. 11/456,376 (2008/0009662A1) the final rejection dated Sep. 23, 2009.
In re the U.S. Appl. No. 11/456,376 (2008/0009662A1) the non-final rejection dated Jan. 7, 2010.
In re the U.S. Appl. No. 11/456,376 (2008/0009662A1) the final rejection dated Jul. 8, 2010.
In re the U.S. Appl. No. 11/456,376 (2008/0009662A1) the advisory action dated Sep. 27, 2010.
In re the U.S. Appl. No. 11/456,376 (2008/0009662A1) the non-final rejection dated Oct. 21, 2010.
In re the U.S. Appl. No. 11/456,376 (2008/0009662A1) the final rejection dated Mar. 29, 2011.
In re the U.S. Appl. No. 11/456,376 (2008/0009662A1) the non-final rejection dated Jul. 14, 2011.
In re the U.S. Appl. No. 11/456,390 (2008/0009931A1) the non-final rejection dated Dec. 10, 2008.
In re the U.S. Appl. No. 11/456,390 (2008/0009931A1) the final rejection dated May 13, 2009.
In re the U.S. Appl. No. 11/456,390 (2008/0009931A1) the non-final rejection dated Sep. 24, 2009.
In re the U.S. Appl. No. 11/456,390 (2008/0009931A1) the final rejection dated Jul. 13, 2010.
In re the U.S. Appl. No. 11/456,402 (2008/0009814A1) the non-final rejection dated Jul. 11, 2007.
In re the U.S. Appl. No. 11/456,402 (2008/0009814A1) the non-final rejection dated Apr. 22, 2008.
In re the U.S. Appl. No. 11/456,402 (2008/0009814A1) the final rejection dated Jan. 7, 2009.
In re the U.S. Appl. No. 11/456,402 (2008/0009814A1) the non-final rejection dated Jun. 5, 2009.
In re the U.S. Appl. No. 11/456,402 (2008/0009814A1) the final rejection dated Dec. 4, 2009.
In re the U.S. Appl. No. 11/456,402 (2008/0009814A1) the advisory action dated Mar. 2, 2010.
In re the U.S. Appl. No. 11/456,402 (2008/0009814A1) the non-final rejection dated Oct. 15, 2010.
In re the U.S. Appl. No. 11/456,402 (2008/0009814A1) the final rejection dated Mar. 30, 2011.
In re the U.S. Appl. No. 11/456,402 (2008/0009814A1) the non-final rejection dated Aug. 18, 2011.
In re the U.S.Appl. No. 11/456,424 (2008/0009663A1) the non-final rejection dated May 23, 2008.
In re the U.S. Appl. No. 11/456,424 (2008/0009663A1) the final rejection dated Sep. 22, 2009.
In re the U.S. Appl. No. 11/456,424 (2008/0009663A1) the non-final rejection dated Jan. 15, 2010.
In re the U.S. Appl. No. 11/456,424 (2008/0009663A1) the final rejection dated Jul. 8, 2010.
In re the U.S. Appl. No. 11/456,424 (2008/0009663A1) the advisory action dated Sep. 29, 2010.
In re the U.S. Appl. No. 11/456,424 (2008/0009663A1) the non-final rejection dated Oct. 21, 2010.
In re the U.S. Appl. No. 11/456,424 (2008/0009663A1) the final rejection dated Mar. 28, 2011.
In re the U.S. Appl. No. 11/456,424 (2008/0009663A1) the non-final rejection dated Jul. 8, 2011.
In re the U.S. Appl. No. 11/456,433 (2008/0009664A1 / U.S. Pat. No. 7,717,892) the non-final rejection dated Aug. 31, 2007.
In re the U.S. Appl. No. 11/456,433 (2008/0009664A1 / U.S. Pat. No. 7,717,892) the notice of allowance dated Apr. 9, 2008.
In re the U.S. Appl. No. 11/456,433 (2008/0009664A1 / U.S. Pat. No. 7,717,892) the non-final rejection dated Aug. 20, 2008.
In re the U.S. Appl. No. 11/456,433 (2008/0009664A1 / U.S. Pat. 7,717,892) the final rejection dated May 6, 2009.
In re the U.S. Appl. No. 11/456,433 (2008/0009664A1 / U.S. Pat. No. 7,717,892) the notice of allowance dated Nov. 23, 2009.
In re the U.S. Appl. No. 11/456,433 (2008/0009664A1 / U.S. Pat. No. 7,717,892) the notice of allowance dated Mar. 25, 2010.
In re the U.S. Appl. No. 11/456,442 (2008/0009666A1 / U.S. Pat. No. 8,047,980) the non-final rejection dated May 28, 2008.
In re the U.S. Appl. No. 11/456,442 (2008/0009666A1 / U.S. Pat. No. 8,047,980) the final rejection dated Sep. 25, 2009.
In re the U.S. Appl. No. 11/456,442 (2008/0009666A1 / U.S. Pat. No. 8,047,980) the non-final rejection dated Jan. 13, 2010.
In re the U.S. Appl. No. 11/456,442 (2008/0009666A1 / U.S. Pat. No. 8,047,980) the final rejection dated Jul. 8, 2010.
In re the U.S. Appl. No. 11/456,442 (2008/0009666A1 / U.S. Pat. No. 8,047,980) the advisory action dated Sep. 27, 2010.
In re the U.S. Appl. No. 11/456,442 (2008/0009666A1 / U.S. Pat. No. 8,047,980) the non-final rejection dated Oct. 21, 2010.
In re the U.S. Appl. No. 11/456,442 (2008/0009666A1 / U.S. Pat. No. 8,047,980) the final rejection dated Mar. 29, 2011.
In re the U.S. Appl. No. 11/456,442 (2008/0009666A1 / U.S. Pat. No. 8,047,980) the notice of allowance dated Jul. 25, 2011.
In re the U.S. Appl. No. 11/456,442 (2008/0009666A1 / U.S. Pat. No. 8,047,980) the notice of allowance dated Sep. 19, 2011.
In re the U.S. Appl. No. 11/776,185 (2008/0033231A1 / U.S. Pat. No. 7,892,163) the non-final rejection dated May 23, 2008.
In re the U.S. Appl. No. 11/776,185 (2008/0033231A1 / U.S. Pat. No. 7,892,163) the final rejection dated Jul. 6, 2009.
In re the U.S. Appl. No. 11/776,185 (2008/0033231A1 / U.S. Pat. No. 7,892,163) the non-final rejection dated Oct. 26, 2009.
In re the U.S. Appl. No. 11/776,185 (2008/0033231A1 / U.S. Pat. No. 7,892,163) the final rejection dated May 11, 2010.
In re the U.S. Appl. No. 11/776,185 (2008/0033231A1 / U.S. Pat. No. 7,892,163) the notice of allowance dated Aug. 25, 2010.
In re the U.S. Appl. No. 11/776,185 (2008/0033231A1 / U.S. Pat. No. 7,892,163) the notice of allowance dated Jan. 10, 2011.
In re the U.S. Appl. No. 12/645,800 the non-final rejection dated May 23, 2012.
In re the U.S. Appl. No. 11/456,376 the non-final rejection dated May 24, 2012.
In re the U.S. Appl. No. 12/776,719 the non-final rejection dated Jun. 29, 2012.
In the U.S. Appl. No. 11/456,376 the final office action dated Dec. 6, 2012.
In the U.S. Appl. No. 12/776,719 the final office action dated Jan. 24, 2013.
In re the U.S. Appl. No. 11/456,376 the non-final office action dated Mar. 11, 2013.
In re the U.S. Appl. No. 13/771,648 the non-final office action dated Apr. 24, 2013.
In the U.S. Appl. No. 12/959,582 the non-final office action dated May 2, 2013.
In re the U.S. Appl. No. 13/756,699 the non-final office action dated Jul. 18, 2013.
In re the U.S. Appl. No. 12/776,719 the Notice of Allowance dated Aug. 29, 2013.
In re the U.S. Appl. No. 11/456,376 the Notice of Allowance dated Sep. 13, 2013.
In re the U.S. Appl. No. 13/771,648 the final office action dated Oct. 7, 2013.
In re the U.S. Appl. No. 12/776,719 the Notice of Allowance dated Nov. 14, 2013.
In re the U.S. Appl. No. 11/456,376 the Notice of Allowance dated Nov. 20, 2013.
In re the U.S. Appl. No. 12/959,582 the Non-final Rejection dated Dec. 2, 2013.
In re the U.S. Appl. No. 13/771,648 the Notice of Allowance dated Dec. 16, 2013.
In re the U.S. Appl. No. 13/756,699 the final office action dated Feb. 6, 2014.
In re the U.S. Appl. No. 13/771,648 the non-final rejection dated Feb. 6, 2014.
In re the U.S. Appl. No. 11/456,390 the non-final rejection dated Mar. 14, 2014.
Braley, S., “The Silicones as Subdermal Engineering Materials”, Annals of the New York Academy of Sciences 146, Materials in Biochemical Engineering, pp. 148-157 (Jan. 1968).
In re the U.S. Appl. No. 11/456,402 the non-final office action dated Apr. 23, 2014.
In re the U.S. Appl. No. 12/959,582 the final office action dated Jun. 20, 2014.
In re the U.S. Appl. No. 11/456,390 the final office action dated Jul. 2, 2014.
In re the U.S. Appl. No. 13/756,699 the non-final office action dated Jul. 3, 2014.
In re the U.S. Appl. No. 12/959,582 the non-final office action dated Oct. 6, 2014.
In re the U.S. Appl. No. 11/456,402 the final office action dated Oct. 31, 2014.
In re the U.S. Appl. No. 13/756,699 the final office action dated Nov. 7, 2014.
Guo Y et al., entitled “Isothermal physical aging characterization of Polyether-ether-ketone (PEEK) and Polyphenylene sulfide (PPS) films by creep and stress relaxation,” Mech Time-Depend Mater (2007) 11: 61-89.
Office Action dated Apr. 22, 2015 in connection with U.S. Appl. No. 11/456,390.
Office Action dated Dec. 26, 2014 in connection with U.S. Appl. No. 12/956,824.
Zhanxiong L et al., entitled “High Temperature Resistant Polymers,” Chemical Industry Press, 2007, 3 pages.
Wang X et al., entitled “Performance, Polymerization and Spinning of Polyetherimide,” Materials Review (2007), 11 pages.
Zhou K et al., entitled “Characteristics, Processing and Application of Polyetherimide,” Technology and Materials, 2003, 5 pages.
Omnexus, entitled “Hardness of different families of thermoplastic elastomers,” internet archive capture from Nov. 7, 2007.
Office Action dated Apr. 3, 2015 in connection with U.S. Appl. No. 12/959,582.
Office Action dated Jul. 15, 2015 in connection with U.S. Appl. No. 13/771,728.
Office Action dated Feb. 9, 2015 in connection with U.S. Appl. No. 13/771,728.
Office Action dated Aug. 12, 2015 in connection with U.S. Appl. No. 12/609,139.
Office Action dated Feb. 10, 2015 in connection with U.S. Appl. No. 12/609,139.
Office Action dated Jun. 24, 2015 in connection with U.S. Appl. No. 12/956,824.
Office Action dated Aug. 17, 2015 in connection with U.S. Appl. No. 11/456,402.
Russian Office Action in connection with Russian Patent Application No. 2012131356, filed Dec. 21, 2010, Decision on Grant.
Japanese Office Action dated Mar. 27, 2015 in connection with Japanese Patent Application No. 2012-546153, Notification of Reasons for Refusal (w/English Translation).
Chinese Office Action dated Dec. 16, 2014 in connection with Chinese Patent Application No. 201180057634.5, Notice of the First Office Action (w/English Translation).
Chinese Office Action dated Feb. 27, 2015 in connection with Chinese Patent Application No. 201280027261.1, Notification of the First Office Action (w/English Translation).
Office Action dated May 23, 2012 in connection with U.S. Appl. No. 12/645,800—non-final rejection.
Related Publications (1)
Number Date Country
20080033230 A1 Feb 2008 US
Continuation in Parts (3)
Number Date Country
Parent 11456376 Jul 2006 US
Child 11776178 US
Parent 11456390 Jul 2006 US
Child 11456376 US
Parent 11456402 Jul 2006 US
Child 11456390 US